Dem­s' $100B deal re­duced fur­ther: Medicare drug price ne­go­ti­a­tions pushed to 13 years for bi­o­log­ics

House De­moc­rats are on the cusp of pass­ing two ma­jor pieces of Biden’s agen­da Fri­day, but Medicare drug price ne­go­ti­a­tions — once the cen­ter­piece of the Build Back Bet­ter Act’s rev­enue stream — has been rel­e­gat­ed to on­ly about $100 bil­lion in sav­ings over the next decade. That num­ber fell low­er yes­ter­day.

Over­all, the com­pro­mise end­ed up win­ning over both De­mo­c­rat sen­a­tors re­ceiv­ing PhRMA cash, like Kyrsten Sine­ma and Bob Menen­dez, and more lib­er­al sen­a­tors, like Eliz­a­beth War­ren. But on the House side, the bat­tle con­tin­ued up un­til yes­ter­day evening.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.